KRAS, the most prevalent oncogenic driver in NSCLC, has been associated with a better response to ICB than patients not harboring variants in KRAS, but the findings have to date been inconclusive [26–31]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.